Erratum for Skotheim et al., J Clin Oncol 21 (24) 4586-4591.

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?

ERRATUM

The D and F panels for Figure 1 were inadvertently transposed. The correct Figure is reprinted below in its entirety.

View larger version (40K): [in this window] [in a new window]   Fig 1. (A) Patients with sporadically occurring malignant peripheral-nerve sheath tumor (MPNSTs), and those predisposed because of neurofibromatosis type I, were included in the study. (B) Genomic profiling. Thirty-eight MPNSTs were initially analyzed by comparative genomic hybridization24 (unpublished data), and increased copy numbers of chromosome arm 17q, distal to the NF1 gene, was seen in 63%. (C) Transcriptional profiling of 636 transcripts on chromosome 17 in MPNST identified several overexpressed genes, and the topoisomerase-II (TOP2A) transcript had the highest average and median overexpression. The intensity of red indicates the expression in the MPNSTs, relative to a pool of three benign neurofibromas. (D) DNA copy number. Fluorescence in situ hybridization analyses of TOP2A (red) along with the centromere on chromosome 17 (green), demonstrated the gene to be amplified on the DNA level in 10 of 16 MPNSTs. (E) Protein expression. In situ analysis of TOP2A protein expression on a tissue microarray revealed positive immunostaining in 83% of the MPNSTs. (F) Survival analysis. A Kaplan-Meier survival plot showed a trend toward association between TOP2A protein expression and poor survival. Due to TOP2A’s role as chemotherapeutic target, it is tempting to speculate whether TOP2A expression is a predictor for chemotherapy response and outcome in MPNST.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?